Shionogi & Co Ltd

Shionogi maintains a strong liquidity position, with a current ratio of 6.63 and cash and equivalents amounting to ¥374.8 billion, which significantly exceeds its short-term obligations. The company's low debt-to-equity ratio of 0.02 indicates a conservative capital structure, with long-term debt of only ¥21.9 billion compared to total equity of ¥1.36 trillion. Profitability metrics show that Shionogi is performing well relative to industry norms. The company's return on equity (ROE) of 12.51% and return on assets (ROA) of 11.1% are strong indicators of efficient capital use and asset management. These figures suggest that Shionogi is generating solid returns for shareholders and effectively deploying its resources. Geographically, Shionogi's revenue is concentrated in Japan, with a significant portion of its sales derived from domestic operations. The company's exposure to international markets is limited, which may present both stability and growth constraints depending on domestic healthcare policy and market dynamics. Looking ahead, Shionogi is projected to maintain a stable growth trajectory, with revenue expected to remain consistent in the current fiscal year and potentially increase in the following year. The company's strong operating cash flow of ¥195.5 billion and free cash flow of ¥89.3 billion support its ability to fund operations and invest in future growth. Risk factors for Shionogi include regulatory changes in the pharmaceutical industry and potential competition in its core therapeutic areas. However, the company's low dilution risk and strong liquidity position mitigate some of these concerns. No immediate filing-based liquidity or dilution flags were detected, indicating a stable capital structure. Recent events, including analyst estimates and price targets, suggest a generally positive outlook for Shionogi. The mean price target of ¥3,480.77 and median price target of ¥3,400.00 reflect a consensus among analysts that the stock is undervalued. The mean recommendation of 2.53, with 2 strong-buy and 3 buy ratings, further supports this view.